KIN - Kindred Biosciences suspends feline recombinant erythropietin program

Kindred Biosciences (KIN) -3.2% after-hours as it discloses the suspension of its feline recombinant erythropoietin program following an "adverse event."Citing the impact of safety profile on the program's potential commercial value as well as the rapid growth of the canine dermatitis market, Kindred says it will redirect resources toward accelerating programs for canine atopic dermatitis.KIN's average Wall Street analyst rating is Very Bullish, while its Quant Rating is Very Bearish.

For further details see:

Kindred Biosciences suspends feline recombinant erythropietin program